m and a

“Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis, representing an unfavorable impact of $1.50 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.”

“AbbVie's full-year 2025 adjusted diluted earnings per share guidance range, including the impact of third quarter 2025 acquired IPR&D and milestones expense, is $10.38 - $10.58.”

“AbbVie's third quarter 2025 adjusted diluted earnings per share guidance range, including the impact of third quarter 2025 acquired IPR&D and milestones expense, is $1.74 - $1.78.”

“Exact Sciences' innovation, its strong brand and customer-focused execution are unrivaled in the cancer diagnostics space, and its presence and strengths are complementary to our own. Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious diseases.”

“Together with Abbott, we can reach more patients, advance earlier detection, and deliver answers that change lives. Abbott's culture of innovation and global commercial reach will help accelerate our mission of eradicating cancer and expanding access to our tests worldwide.”

“We had a terrific and very active third quarter! For our combined brokerage and risk management segments, we delivered 20% total revenue growth; our 19th straight quarter of double-digit top-line growth.”

If you're building in healthcare or selling into hospital systems, JNJ's accelerating MedTech spend — especially in electrophysiology, AI-powered surgical tools like VIRTUGUIDE, and cardiovascular devices — signals strong institutional budgets and appetite for innovation in surgical workflows.

If you sell into automotive OEMs, budget cycles are getting longer and more complex as suppliers like Aptiv restructure. But if you build edge AI, robotics, or industrial automation solutions, Aptiv's aggressive pivot into non-auto markets signals real demand from a $12B+ buyer willing to invest organically and via M&A.

If you're selling into pharma or hospital systems, KEYTRUDA subcutaneous approval (one-minute administration) is about to reshape infusion center economics — watch for procurement cycle changes in oncology clinics.

If you're building on cloud infrastructure, Oracle is aggressively competing on price and availability with 211+ regions. Their multicloud strategy means your enterprise customers may start requesting Oracle database deployments inside their existing AWS/Azure environments — be ready to support that.

If you're building insurtech or selling into risk management budgets, the spend environment is healthy — Aon's broad-based growth signals enterprise buyers are actively investing in risk and benefits advisory, not cutting.

If you're selling into insurance brokerages or risk management buyers, budgets are expanding — AJG alone added 10,900 employees in one quarter via acquisition. This is a sector consolidating fast; partner early or get squeezed out.

If you're selling into industrial gas or clean energy infrastructure, expect delayed timelines and tighter vendor scrutiny as APD rationalizes its project portfolio. Their $4B capex plan for FY2026 signals continued spending but with far more discipline on returns.

If you sell into semiconductor fabs or advanced packaging supply chains, DuPont's 10% organic electronics growth confirms the AI capex wave is hitting materials suppliers — budget cycles are expanding, not contracting.

If you're selling into grocery retail or food distribution, expect private label pressure and tighter shelf-space decisions. Brands that can't prove velocity are getting cut.

If you're selling into retail or supply chain digitization, the RFID/intelligent labels wave is real and accelerating — Avery's Solutions Group growth confirms enterprise buyers are actively spending here even as broader materials demand softens.

If you're building AI hardware or custom silicon, Cadence's record backlog and AI/HPC-driven hardware expansion signal that chip design tooling demand is surging — budget cycles for EDA tools are expanding, not contracting.

If you're building custom silicon or AI accelerators, Cadence's expanding portfolio and AI-centric tools mean the design toolchain is getting richer — budget for deeper EDA spend but expect faster tapeout cycles.

If you're building anything adjacent to theatrical distribution or experiential entertainment, the recovery is real but fragile — it's entirely dependent on studio release cadence, not structural demand growth.

If you're building security tools, CrowdStrike's platform consolidation play is swallowing adjacent categories fast — cloud security, identity, SIEM. Either integrate with Falcon or find a niche they haven't reached yet. If you're a buyer, Falcon Flex pricing creates real consolidation leverage worth evaluating.

If you're selling into commercial construction or building security, buyer budgets are healthy and pricing power is holding. This is a green light to push enterprise deals — procurement isn't squeezing vendors in this category right now.

If you're building in proptech or adjacent to real estate marketplaces, CoStar is flooding the zone with capital and AI-powered search. Their Homes.com network at 115M monthly uniques makes them a platform you either integrate with or get steamrolled by.

If you're building for public safety or enterprise physical security, Axon is consolidating the stack fast — from body cams to 911 dispatch to drones. Either integrate into their ecosystem or prepare to compete against a $2.7B-revenue platform with $11.4B in contracted backlog.

If you're building proptech or selling into multifamily operators in the Southeast, budget cycles are getting squeezed — NOI compression plus rising insurance and payroll costs mean operators have less discretionary spend. Texas properties are the weakest link with revenue down 7% YoY.

If you're building in pharma/biotech services, AbbVie's $2.7B IPR&D spend signals aggressive pipeline acquisition — expect continued deal flow and integration demand in the pharma services ecosystem.

If you're building in diagnostics, cancer screening, or precision oncology, Abbott just became a much bigger competitor with $12B+ in annual diagnostics revenue post-close. Exact Sciences' distribution will accelerate under Abbott's 160-country footprint.

If you're selling into athletic or lifestyle brands, expect procurement freezes and vendor consolidation as UA rationalizes contracts and headcount through FY2026.

If you're building connected building infrastructure or selling into healthcare/education facilities, A. O. Smith is aggressively expanding its mechanical-room footprint — expect them as a bundled competitor for water management systems.

If you sell into any Celanese end-market — auto, industrial, construction, coatings — budget cycles are frozen. Their entire strategy is cost-cutting and deleveraging, not growth investment. Don't expect procurement teams at materials companies to greenlight new vendor relationships until demand visibly turns.

If you sell into Cencora's non-core units (animal health, consulting, PharmaLex components), watch for divestitures — your buyer may change.

If you sell into enterprise IT, IBM's clients are spending — especially on AI transformation and infrastructure modernization. The z17 cycle and AI consulting demand signal real budget allocation, not just pilots. Position your product as part of the AI deployment stack, not a net-new budget line.

If you're building in the streaming, media, or content tech stack, Netflix just became a significantly larger buyer and competitor. The combined content library and distribution footprint will reshape licensing, ad inventory, and platform economics.

If you're building in European BNPL or embedded lending, PayPal is scaling aggressively with institutional capital backing — expect them to be a more aggressive competitor in EU markets through 2028.